Answers are grounded in this paper and cite their sources.
Companies are engineering B cells to produce gene-encoded medicines, but clinical proof of concept is needed to convince the doubters that this platform can deliver.
No takes yet. Share an insight, caveat, or question.
Cormac Sheridan (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: